Botanical species · safety record

Rauvolfia serpentina

The EFSA Compendium of Botanicals holds 16 constituent measurements and 1 adverse-effect record for Rauvolfia serpentina. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Rauvolfia serpentina (L.) Benth. ex Kurz

16Constituent measurements

1Safety records

7Cited sources

0Licensed products (Canada)

Also recorded as

Ophioxylon serpentinum L.
Ophioxylon trifoliatum Gaertn.
Rauvolfia trifoliata (Gaertn.) Baill.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Ajmalicine	Roots and other underground parts	Solvent extraction	≤ 0.17 Percent	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	Resolve DOI
Ajmalicine	Roots and other underground parts	Solvent extraction	—	HPLC-MS/MS	Resolve DOI
Ajmalicine	Roots and other underground parts	Solvent extraction	≥ 0.16 Percent	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	Resolve DOI
Ajmalicine	Roots and other underground parts	Solvent extraction	—	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	Resolve DOI
Indole alkaloids	Roots and other underground parts	Solvent extraction	—	HPLC-MS/MS	Resolve DOI
Indole alkaloids	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Indole alkaloids	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Indole alkaloids	Roots and other underground parts	Solvent extraction	—	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	Resolve DOI
Indole alkaloids	Roots and other underground parts	Solvent extraction	—	HPLC-MS/MS	Resolve DOI
Reserpine	Roots and other underground parts	Solvent extraction	≥ 0.17 Percent	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	Resolve DOI
Reserpine	Roots and other underground parts	Solvent extraction	—	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	Resolve DOI
Reserpine	Roots and other underground parts	Solvent extraction	—	HPLC-MS/MS	Resolve DOI
Reserpine	Roots and other underground parts	Solvent extraction	≤ 0.18 Percent	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	Resolve DOI
Reserpine	Unspecified	Solvent extraction	—	Unspecified	Resolve DOI
Yohimbine	Roots and other underground parts	Solvent extraction	—	HPLC-MS/MS	Resolve DOI
Yohimbine	Roots and other underground parts	Solvent extraction	—	Gelpermeation, High Performance Thin Layer Chromatography (HPTLC)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Endocrine	Digestive: pancreas	Roots and other underground parts	Solvent extraction	House mouse (as animal)	Acute toxicity	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Pandey, Devendra Kumar., Radha., Dey, Abhijit. A validated and densitometric HPTLC method for the simultaneous quantification of reserpine and ajmalicine in Rauvolfia serpentina and Rauvolfia tetraphylla . Revista brasileira de farmacognosia-brazilian journal of pharmacognosy, 2016, vol. 26, no. 5, p. 553-557. DOI
Kumar, Sunil., Singh, Awantika., Bajpai, Vikas., Srivastava, Mukesh., Singh, Bhim Pratap., Kumar, Brijesh. Structural characterization of monoterpene indole alkaloids in ethanolic extracts of Rauwolfia species by liquid chromatography with quadrupole time-of-flight mass spectrometry . Journal of pharmaceutical analysis, 2016, vol. 6, no. 6, p. 363-373. DOI
Azmi, Muhammad Bilal., Qureshi, Shamim A. Methanolic Root Extract of Rauwolfia serpentina Improves the Glucose Tolerance in Wister Mice . Journal of food and drug analysis, 2012, vol. 20, no. 2, p. 484-488. DOI
Klyushnichenko, V. E., Yakimov, S. A., Tuzova, T. P., Syagailo, Ya. V., Kuzovkina, I. N., Wulfson, A. N., Miroshnikov, A. I. Determination of indole alkaloids from R. serpentina and R. vomitoria by high-performance liquid chromatography and high-performance thin-layer chromatography. Journal of chromatography a, 1995, vol. 704, no. 2, p. 357-62.
Gupta, Madan Mohan., Srivastava, Alpana., Tripathi, Arvind Kumar., Misra, Himanshu., Verma, Ram Kishore. Use of HPTLC, HPLC, and densitometry for qualitative separation of indole alkaloids from Rauvolfia serpentina roots . Jpc-journal of planar chromatography-modern tlc, 2006, vol. 19, no. 110, p. 282-287. DOI
Itoh, A., Kumashiro, T., Yamaguchi, M., Nagakura, N., Mizushina, Y., Nishi, T., Tanahashi, T. Indole alkaloids and other constituents of Rauwolfia serpentina. Journal of natural products, 2005, vol. 68, no. 6, p. 848-852. DOI
Abdelfatah, Sara A. A., Efferth, Thomas. Cytotoxicity of the indole alkaloid reserpine from Rauwoffia serpentina against drug-resistant tumor cells . Phytomedicine, 2015, vol. 22, no. 2, p. 308-318. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature